RXi Pharmaceuticals is a biotech company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. RXi’s first RNAi product candidate, RXI-109, entered into RXi’s first human clinical trial in 2012. The candidate is initially being developed to reduce or inhibit scar formation in the skin following surgery. For further information, visit the company’s Web site at www.rxipharma.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: